Stock listing
HKEX:9637 Alebund Pharmaceuticals (Jiangsu) Limited (禮邦醫藥) 股價
Follow Alebund Pharmaceuticals (Jiangsu) Limited into a list and get an email when it puts out news.
Share price · HKEX:9637
$20.30 HKD +0.35 (+1.8%)
Close on Nov 20, 2026
- Day range
- $19.33 – $20.50 HKDNov 20, 2026
- Volume
- 170,700 sharesNov 20, 2026
- Market cap
- $4.77B HKDAt the close on Nov 20, 2026 · price × 235.1M shares outstanding
- Traded on an average day
- $18.04M HKDMedian day 565,650 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:9637 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $20.30 | +0.35 | +1.8% | $19.33 | $20.50 | $19.33 | 170,700 | |
| $19.95 | 0.00 | 0.0% | $19.60 | $20.08 | $19.27 | 429,600 | |
| $19.95 | -0.15 | -0.7% | $20.86 | $20.86 | $19.52 | 321,500 | |
| $20.10 | -0.50 | -2.4% | $20.60 | $20.88 | $19.81 | 447,800 | |
| $20.60 | -0.62 | -2.9% | $20.92 | $21.16 | $19.39 | 621,800 | |
| $21.22 | +0.22 | +1.0% | $20.46 | $21.60 | $20.46 | 235,800 | |
| $21.00 | +1.00 | +5.0% | $19.98 | $21.02 | $19.88 | 416,000 | |
| $20.00 | +0.39 | +2.0% | $20.30 | $20.30 | $19.29 | 468,649 | |
| $19.61 | +0.43 | +2.2% | $19.19 | $20.00 | $19.19 | 567,900 | |
| $19.18 | +0.71 | +3.8% | $18.00 | $19.55 | $17.98 | 659,317 | |
| $18.47 | +1.07 | +6.1% | $17.80 | $18.88 | $17.28 | 1,031,965 | |
| $17.40 | +0.89 | +5.4% | $16.98 | $17.40 | $15.65 | 1,012,435 | |
| $16.51 | -0.79 | -4.6% | $17.30 | $18.03 | $16.00 | 1,772,800 | |
| $17.30 | +1.16 | +7.2% | $16.14 | $17.49 | $15.20 | 699,662 | |
| $16.14 | -0.60 | -3.6% | $16.74 | $16.79 | $15.84 | 210,562 | |
| $16.74 | +0.02 | +0.1% | $17.18 | $17.22 | $16.42 | 363,000 | |
| $16.72 | +0.38 | +2.3% | $16.34 | $16.94 | $15.85 | 669,097 | |
| $16.34 | +0.39 | +2.4% | $15.95 | $17.78 | $15.72 | 1,588,521 | |
| $15.95 | +0.36 | +2.3% | $15.00 | $15.95 | $14.80 | 381,700 | |
| $15.59 | +0.09 | +0.6% | $15.56 | $16.20 | $14.36 | 742,089 | |
| $15.50 | -1.48 | -8.7% | $17.13 | $17.35 | $15.21 | 1,106,741 | |
| $16.98 | +0.11 | +0.7% | $18.00 | $19.33 | $16.90 | 2,574,300 | |
| $16.87 | -0.61 | -3.5% | $17.48 | $25.74 | $16.81 | 7,402,116 | |
| $17.48 | -1.14 | -6.1% | $19.00 | $19.63 | $16.89 | 1,866,729 | |
| $18.62 | -3.36 | -15.3% | $21.98 | $21.98 | $18.62 | 471,600 | |
| $21.98 | -0.24 | -1.1% | $22.22 | $23.14 | $21.52 | 509,600 | |
| $22.22 | -2.58 | -10.4% | $24.80 | $24.80 | $22.00 | 572,100 | |
| $24.80 | -1.50 | -5.7% | $26.80 | $26.80 | $24.70 | 571,919 | |
| $26.30 | -0.70 | -2.6% | $27.10 | $27.10 | $26.00 | 517,400 | |
| $27.00 | -1.58 | -5.5% | $28.26 | $28.80 | $25.50 | 685,700 | |
| $28.58 | +1.92 | +7.2% | $26.68 | $29.00 | $25.68 | 533,470 | |
| $26.66 | +0.36 | +1.4% | $26.30 | $27.10 | $25.76 | 234,168 | |
| $26.30 | +0.90 | +3.5% | $25.40 | $26.90 | $25.30 | 227,352 | |
| $25.40 | +0.42 | +1.7% | $24.88 | $25.54 | $24.60 | 206,700 | |
| $24.98 | +0.28 | +1.1% | $24.96 | $25.78 | $24.56 | 459,734 | |
| $24.70 | +1.26 | +5.4% | $24.12 | $25.28 | $23.54 | 631,600 | |
| $23.44 | -1.34 | -5.4% | $24.82 | $24.82 | $23.12 | 517,300 | |
| $24.78 | -1.12 | -4.3% | $26.00 | $26.30 | $24.22 | 224,900 | |
| $25.90 | +0.20 | +0.8% | $25.68 | $25.90 | $24.80 | 447,600 | |
| $25.70 | -0.56 | -2.1% | $26.40 | $26.84 | $25.70 | 278,900 | |
| $26.26 | -0.50 | -1.9% | $26.30 | $28.40 | $26.14 | 728,500 | |
| $26.76 | +1.34 | +5.3% | $26.36 | $27.70 | $25.70 | 1,042,900 | |
| $25.42 | -0.64 | -2.5% | $26.60 | $27.50 | $24.70 | 846,592 | |
| $26.06 | +1.94 | +8.0% | $24.12 | $26.40 | $23.14 | 1,053,500 | |
| $24.12 | +0.54 | +2.3% | $23.50 | $24.92 | $22.68 | 1,184,800 | |
| $23.58 | +0.58 | +2.5% | $23.68 | $27.50 | $22.78 | 2,730,220 | |
| $23.00 | -1.02 | -4.2% | $24.06 | $24.78 | $22.48 | 350,700 | |
| $24.02 | -0.98 | -3.9% | $25.00 | $25.30 | $23.82 | 563,400 | |
| $25.00 | -0.74 | -2.9% | $26.96 | $26.96 | $24.50 | 772,700 | |
| $25.74 | -2.24 | -8.0% | $28.98 | $28.98 | $24.06 | 1,582,700 | |
| $27.98 | +1.08 | +4.0% | $26.90 | $28.94 | $26.90 | 1,060,792 | |
| $26.90 | -1.90 | -6.6% | $29.12 | $29.12 | $25.80 | 2,845,723 | |
| $28.80 | +0.30 | +1.1% | $28.42 | $29.32 | $28.10 | 616,300 | |
| $28.50 | -0.40 | -1.4% | $28.76 | $29.90 | $27.26 | 329,240 | |
| $28.90 | -1.56 | -5.1% | $30.20 | $30.68 | $27.54 | 718,600 | |
| $30.46 | -1.02 | -3.2% | $31.24 | $32.78 | $30.46 | 302,600 | |
| $31.48 | +0.22 | +0.7% | $30.64 | $32.00 | $30.44 | 233,502 | |
| $31.26 | +0.12 | +0.4% | $31.00 | $31.72 | $30.02 | 241,496 | |
| $31.14 | -1.86 | -5.6% | $32.86 | $33.62 | $31.00 | 569,100 | |
| $33.00 | -0.90 | -2.7% | $34.24 | $34.36 | $33.00 | 585,500 | |
| $33.90 | +1.44 | +4.4% | $31.14 | $34.78 | $31.14 | 488,600 | |
| $32.46 | -0.66 | -2.0% | $32.78 | $34.80 | $31.62 | 282,700 | |
| $33.12 | -0.22 | -0.7% | $33.30 | $34.00 | $32.26 | 301,300 | |
| $33.34 | +0.16 | +0.5% | $33.00 | $35.46 | $33.00 | 287,285 |
- Ticker
- HKEX:9637
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- HKEX
- Currency
- HKD
What changed lately
Latest news release · Nov 20, 2026
Next Day Disclosure Return
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Nov 4, 2026
Closed $18.47 (+6.1%) on Nov 5, 2026
Voluntary announcement - on-market share repurchase
Oct 20, 2026
Closed $16.98 (+0.7%) on Oct 21, 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Oct 6, 2026
Closed $28.58 (+7.2%) on Oct 7, 2026
2026 Interim report
Sep 17, 2026
Closed $25.42 (-2.5%) on Sep 18, 2026
Alebund's AP301 NDA Accepted for Review by China's NMPA
Aug 7, 2026
Closed $35.88 (+9.8%) on Aug 10, 2026
Alebund Pharmaceuticals (Jiangsu) Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 20 in all · newest Nov 20, 2026 · oldest 2026
Valuation
EV/sales 106× against a median of 1.9×: the highest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.79B HKD
- P/E
- Loss
- EV/sales
- 106×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.9×
- Gross margin
- 44.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.4×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Gubra A/S · OMXCOP:GUBRA | US$638.5M | US$533.6M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Kura Oncology, Inc. · NASDAQ:KURA | US$634.9M | US$152.6M | n/a | 1.9× | n/a | 35.4× | −369.3% | 0.6× | 1.30 |
| Alphamab Oncology · HKEX:9966 | US$628.9M | US$454.7M | n/a | 5.5× | n/a | 2.5× | −20.1% | 0.2× | n/a |
| Iambic Therapeutics, Inc. · NASDAQ:IAM | US$621.4M | US$369.4M | n/a | 39.2× | n/a | n/a | −820.0% | n/a | n/a |
| Janux Therapeutics, Inc. · NASDAQ:JANX | US$616.7M | −US$308.6M | n/a | −13.3× | n/a | 0.7× | −428.7% | 0.0× | 0.95 |
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Design Therapeutics, Inc. · NASDAQ:DSGN | US$577.6M | US$371.5M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.29 |
| Cullinan Therapeutics, Inc. · NASDAQ:CGEM | US$577.1M | US$289.6M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 1.45 |
| Median of the others | US$619.1M | US$370.5M | 2.6× | 1.9× | 1.7× | 2.6× | −369.3% | 0.0× | 1.30 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 48.73 HKD · Analysts' mean
- EPS, year to Dec 2026
- -1.46 · 1 analyst
- Revenue, year to Dec 2026
- 153.9M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin XIA | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Huading ZHANG | Chief Operating Officer |
| Jin TIAN | Co-Founder and Chief Medical Officer |
| WANG Yun | Chief of Staff |
Board
| Director | Role |
|---|---|
| Gavin XIA | Co-Founder, Chief Executive Officer and Chairman of the Board |
| An LU | Non-Executive Director |
| Huading ZHANG | Chief Operating Officer |
| Jin TIAN | Co-Founder and Chief Medical Officer |
| Justin LEUNG | Independent Non-Executive Director |
| Shirley XU | Independent Non-Executive Director |
| WANG Yun | Chief of Staff |
| Zhui CHEN | Independent Non-Executive Director |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 30.6M | 6.53M |
| Cost of revenue | 17.1M | 4.14M |
| Gross profit | 13.4M | 2.38M |
| Research and development | 372.6M | 235.4M |
| Selling, general and administrative | 52.1M | 17.2M |
| Operating income | -641.3M | -306.9M |
| Depreciation and amortization | 44.7M | 12.5M |
| EBITDA | -596.5M | -294.4M |
| Interest expense | 110.5M | 29.4M |
| Income before tax | -751.8M | -335.1M |
| Net income | -750.0M | -326.0M |
| Earnings per share, basic | -2.21 | -0.96 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 358.3M | 343.8M |
| Short-term investments | 172.8M | 22.3M |
| Receivables | 0 | 865.0K |
| Inventory | 10.3M | 6.12M |
| Current assets | 558.7M | 388.8M |
| Total assets | 1.34B | 1.11B |
| Accounts payable | 67.8M | 25.9M |
| Current liabilities | 239.8M | 1.94B |
| Long-term debt | 545.3M | 445.3M |
| Total liabilities | 836.7M | 2.45B |
| Shareholders' equity | 503.2M | -1.33B |
| Shares outstanding | 339.9M | 339.9M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -287.9M | -249.9M |
| Capital spending | -101.6M | -236.7M |
| Free cash flow | -389.5M | -486.6M |
| Change in cash | 17.0M | 280.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Next Day Disclosure Return | Nov 20, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 19, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 18, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 17, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 16, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 13, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 6, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 5, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 4, 2026 | Next day disclosure return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026 | Nov 4, 2026 | Monthly return | HKEX |
All 19 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Next Day Disclosure Return | Nov 3, 2026 | Next day disclosure return | HKEX |
| Next Day Disclosure Return | Nov 2, 2026 | Next day disclosure return | HKEX |
| VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | Oct 20, 2026 | Other filings | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026 | Oct 6, 2026 | Monthly return | HKEX |
| 2026 INTERIM REPORT | Sep 17, 2026 | Interim report | HKEX |
| ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | Jun 26, 2026 | Financing | HKEX |
| LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | Jun 25, 2026 | List of directors | HKEX |
| Documents on Display | Jun 17, 2026 | Other filings | HKEX |
| PHIP (1st submission) | Jun 14, 2026 | Other filings | HKEX |
Cap table
Built by 6ix from Alebund Pharmaceuticals (Jiangsu) Limited Class H’s releases
- Common shares
- 235,131,589
- Fully diluted
- 235,131,589
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 235,131,589 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 235,131,589 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| An LU | Non-Executive Director · Since at least Nov 5, 2026 |
| Gavin XIA | Co-Founder, Chief Executive Officer and Chairman of the Board · Since at least Aug 7, 2026 |
| Huading ZHANG | Chief Operating Officer · Since at least Nov 5, 2026 |
| Jin TIAN | Co-Founder and Chief Medical Officer · Since at least Aug 7, 2026 |
| Justin LEUNG | Independent Non-Executive Director · Since at least Nov 5, 2026 |
| Shirley XU | Independent Non-Executive Director · Since at least Nov 5, 2026 |
| WANG Yun | Chief of Staff · Since at least Nov 5, 2026 |
| Zhui CHEN | Independent Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Alebund Pharmaceuticals (Jiangsu) Limited.